KT-413, a Novel IRAKIMiD Degrader of IRAK4 and IMiD Substrates, has a Differentiated MOA that Leads to Single-agent and Combination Regressions in MYD88MT Lymphoma Models

Michele Mayo, Rahul Karnik, Christine Klaus, Atanu Paul, Kirti Sharma, Alice McDonald, Duncan Walker, Matthew Weiss
Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA) and other federal securities laws. These statements include information about our current and future prospects and our operations and financial results, which are based on currently available information. All statements other than statements of historical facts contained in this presentation, including express or implied statements regarding our strategy, future financial condition, future operations, projected costs, prospects, plans, objectives of management and expected market growth, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “predict,” “positioned,” “potential,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. These forward-looking statements include statements about the initiation, timing, progress and results of our future clinical trials and current and future preclinical studies of our product candidates and of our research and development programs; our plans to develop and commercialize our current product candidates and any future product candidates and the implementation of our business model and strategic plans for our business, current product candidates and any future product candidates. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, the occurrence of certain events or otherwise. As a result of these risks and others, including those set forth in our most recent and future filings with the Securities and Exchange Commission, actual results could vary significantly from those anticipated in this presentation, and our financial condition and results of operations could be materially adversely affected. This presentation contains trademarks, trade names and service marks of other companies, which are the property of their respective owners.

Certain information contained in this presentation and statements made orally during this presentation relate to or is based on studies, publications, surveys and other data obtained from third-party sources and the Company's own internal estimates and research. While the Company believes these third-party studies, publications, surveys and other data to be reliable as of the date of the presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, no independent sources has evaluated the reasonableness or accuracy of the Company's internal estimates or research and no reliance should be made on any information or statements made in this presentation relating to or based on such internal estimates and research.
Financial Disclosures

Michele Mayo, Rahul Karnik, Christine Klaus, Atanu Paul, Kirti Sharma, Alice McDonald, Duncan Walker, Matthew Weiss

Kymera Therapeutics Employment and Equity Ownership
• Single-agent therapies that target activated NFκB signaling in DLBCL show limited activity in preclinical or clinical settings

• Redundant NFκB pathway activation and downregulation of Type 1 IFN is common in MYD88<sup>MT</sup> lymphoma, supporting need to seek combination therapies

• Targeting simultaneous degradation of IRAK4 and IMiD substrates Ikaros and Aiolos shows synergistic activity in MYD88<sup>MT</sup> models, supporting this targeted combination

* Pathway activating alterations in DLBCL

Adapted from Yang et al. (2012) Cancer Cell 21, 6, pp723-737
KT-413 is a Potent Degrader of IRAK4 and IMiD Substrates with Activity in MYD88\textsuperscript{MT} Cell lines

- KT-413 selectively degrades both IRAK4 and IMiD substrates.
- KT-413 substrate degradation is hierarchical: IRAK4 degradation is slower than Ikaros and Aiolos.
- KT-413 is more active in MYD88\textsuperscript{MT} DLBCL cells than the clinically active IMiD, CC-220, and an IRAK4-selective degrader, KTX-545, both in potency and in the maximal level of cell growth inhibition achieved.

<table>
<thead>
<tr>
<th>Compound</th>
<th>IRAK4 DC\textsubscript{50} (nM)</th>
<th>Ikaros DC\textsubscript{50} (nM)</th>
<th>Aiolos DC\textsubscript{50} (nM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>KT-413</td>
<td>6</td>
<td>2</td>
<td>2</td>
</tr>
</tbody>
</table>

**KT-413 at 41 nM**

**OCI-Ly10**

**SUDHL2**
IMiDs or IRAK4-Selective Degrader Alone Cannot Fully Target Both NFκB and IFN Pathways

KTX-545, an IRAK4-selective degrader, selectively targets MYD88-NFκB signaling
- Partially downregulates IKK signaling
- Redundant pathway signaling maintains NFκB activity
- No impact on Type I IFN signaling
- Does not induce significant apoptosis

MYD88<sup>MT</sup> OCI-Ly10 cells treated with compounds for 48h at ~10X DC50

DMSO
KTX-545
CC-220
KT-413

IKKβ
Phospho IKKα/β
p65
Phospho p65

IRAK4
Aiolos
IRF4
IRF7
IFIT1

Apoptosis
Cleaved Caspase 3
IMiDs or IRAK4-Selective Degrader Alone Cannot Fully Target Both NFκB and IFN Pathways

**CC-220 selectively targets Type 1 IFN signaling**
- Partially downregulates NFκB signaling
- Activates Type 1 IFN signaling
- Drives Type1-IFN-dependent apoptosis

**MYD88^{MT} OCI-Ly10 cells treated with compounds for 48h at ~10X DC50**
IRAKIMiD KT-413 degrades both IRAK4 and IMiD substrates
- Strongly downregulates NFκB signaling
- Overcomes redundant pathway activation
- Greater activation of Type 1 IFN signaling
- Drives strong and rapid apoptosis

MYD88<sup>MT</sup> OCI-Ly10 cells treated with compounds for 48h at ~10X DC50

IRAK4

IRAKIMiD KT-413 drives apoptosis by effectively targeting both NFκB and IFN signaling.
**KT-413 Preferentially Modulates Cell Cycle and Apoptosis Pathways Compared to IMiDs or IRAK4-Selective Degradation**

- Transcriptomics analysis in OCI-Ly10 after 48h shows preferential downregulation of NFκB and upregulation of IFN signaling leading to downregulated cell cycle pathways and apoptosis signals consistent with greater and more potent KT-413 activity compared to IMiDs and IRAK4-selective targeting.

### DNA Replication / NFκB Signaling / Cell cycle

<table>
<thead>
<tr>
<th>Condition</th>
<th>IRF7</th>
<th>IRF4</th>
<th>NFKB2</th>
<th>RELB</th>
</tr>
</thead>
<tbody>
<tr>
<td>DMSO</td>
<td>4.9e-65</td>
<td>3.1e-74</td>
<td>2.6e-17</td>
<td>7.2e-05</td>
</tr>
<tr>
<td>KT-413</td>
<td>3.1e-08</td>
<td>1.4e-08</td>
<td>2.5e-17</td>
<td>0.00038</td>
</tr>
<tr>
<td>CC220</td>
<td>0.71</td>
<td>0.39</td>
<td>2.6e-10</td>
<td>0.0055</td>
</tr>
<tr>
<td>KT-413</td>
<td>0.71</td>
<td>0.39</td>
<td>2.6e-10</td>
<td>0.0055</td>
</tr>
</tbody>
</table>

### Interferon Signaling

<table>
<thead>
<tr>
<th>Gene</th>
<th>Transcripts per Million</th>
</tr>
</thead>
<tbody>
<tr>
<td>POLD1</td>
<td>3.2e-09</td>
</tr>
<tr>
<td>LIG1</td>
<td>3.1e-11</td>
</tr>
<tr>
<td>AURKB</td>
<td>9.6e-11</td>
</tr>
<tr>
<td>KIFC1</td>
<td>3.1e-07</td>
</tr>
</tbody>
</table>

### Downregulated Cell Cycle Pathways

- **POLD1**: DNA polymerase delta
- **LIG1**: DNA ligase 1
- **AURKB**: Aurora kinase B
- **KIFC1**: Kinesin family member C1
- **CENPA**: Centromere protein A
- **DSCC1**: DNA replication and sister chromatid cohesion 1
- **STMN1**: Stathmin 1

**KT-413 shows similar activation of Type1 IFN and greater downregulation of NFκB pathway transcription...**

...leading to downregulation of genes involved in DNA replication and the cell cycle.
KT-413 is Highly Active on Intermittent Dosing Regimens

- In the OCI-Ly10 MYD88MT xenograft model, intermittent dosing of KT-413 induced strong antitumor activity, including complete or partial regressions
  - Superior activity compared to the clinically active IRAK4-inhibitor CA-4948 or the IMiD CC-220 alone
- Minimally active dose of 3 mg/kg D1,2 showed extended tumor exposure and strong degradation of both IRAK4 and IMiD substrates that was maintained for at least 72h

<table>
<thead>
<tr>
<th>Drug</th>
<th>CR</th>
<th>PR</th>
<th>SD</th>
<th>PD</th>
</tr>
</thead>
<tbody>
<tr>
<td>CA-4948</td>
<td>0</td>
<td>0</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>CC-220</td>
<td>0</td>
<td>1</td>
<td>4</td>
<td>2</td>
</tr>
<tr>
<td>KT-413 (5 mpk)</td>
<td>2</td>
<td>2</td>
<td>3</td>
<td>-</td>
</tr>
<tr>
<td>KT-413 (10 mpk)</td>
<td>5</td>
<td>2</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

CR: <10mm³ tumor on D26
PR: >50% regression from baseline
SD: <50% regression to 20% increase in tumor volume
PD: >20% tumor growth on D26

Days after the Start of Treatment

Tumor Volume (mm³)

0 5 10 15 20 25 30 35

Vehicle
CA-4948, 150 mg/kg, PO, QD x 28
CC-220, 3 mg/kg POQDx21
KT-413, 10 mg/kg, IV, D1,2,21,22
KT-413, 5 mg/kg, IV D1,2 15,16

Days after the Start of Treatment

Tumor Volume (mm³)
KT-413 Shows Regressions in MYD88\textsuperscript{MT} Patient-Derived Xenograft (PDX) Models

<table>
<thead>
<tr>
<th>Model</th>
<th>MYD88</th>
<th>CD79B</th>
<th>TNFAIP3</th>
<th>Other</th>
<th>KT-413 (%TGI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>LY14019</td>
<td>L265P</td>
<td>MT</td>
<td>MT</td>
<td></td>
<td>100</td>
</tr>
<tr>
<td>LY2264</td>
<td>L265P</td>
<td>MT</td>
<td></td>
<td>IRF4</td>
<td>100</td>
</tr>
<tr>
<td>LY2298</td>
<td>L265P</td>
<td>MT</td>
<td></td>
<td>BCL2/BCL6</td>
<td>90</td>
</tr>
<tr>
<td>LY12699</td>
<td>L265P</td>
<td>MT</td>
<td></td>
<td></td>
<td>87</td>
</tr>
<tr>
<td>LY2345</td>
<td>WT</td>
<td>MT</td>
<td></td>
<td></td>
<td>70</td>
</tr>
<tr>
<td>LY2301</td>
<td>WT</td>
<td></td>
<td></td>
<td></td>
<td>30</td>
</tr>
<tr>
<td>LY0257</td>
<td>L265P</td>
<td></td>
<td></td>
<td>BCL2/BCL6/IKZF3</td>
<td>0</td>
</tr>
</tbody>
</table>

PTX Ly14019\textsuperscript{CD79mut/MYD88L265Pmut}

- Tumor Volume (mm\textsuperscript{3}) Median
  - Vehicle
  - KT-413, 20 mg/Kg
  - PO D1-3 QW

KT-413 shows strong tumor growth inhibition (>85% TGI) in 4/5 MYD88-Mutated DLBCL PDX Models

- Activity is observed regardless of co-mutations that activate NFkB and IRF4 pathways
- The non-responsive MYD88\textsuperscript{MT} model LY0257 harbors a mutation in Aiolos and is reported to be insensitive to lenalidomide. The functional consequence of Aiolos mutations in IRAKIMiD and IMiD response is being investigated

Some level of tumor growth inhibition observed in MYD88-WT PDX

- May be consistent with IMiD activity of KT-413

PDX models run at Crown Biosciences
KT-413 Has Additive Antitumor Activity in Combination with Ibrutinib in MYD88\textsuperscript{MT} OCI-Ly10 Xenografts

- KT-413 administered on intermittent schedules demonstrated additive activity with strong regressions in combination with the BTK inhibitor Ibrutinib.
KT-413 Has Supra-Additive Antitumor Activity in Combination with Venetoclax in MYD88<sup>MT</sup> OCI-Ly10 Xenografts

- KT-413 administered on intermittent schedules demonstrated supra-additive* activity with deep and durable regressions in combination with the BCL-2 inhibitor, Venetoclax

* Determined by Bliss Independence method
KT-413 Has Supra-Additive Antitumor Activity in Combination with Rituxan in MYD88\textsuperscript{MT} OCI-Ly10 Xenografts

- KT-413 administered on intermittent schedules demonstrated deep and durable regressions in combination with Rituxan

- KT-413 + Rituxan showed strong tumor regressions in tumors that relapsed following initial R-CHOP treatment

\*Determined by Bliss Independence method
Conclusions

- KT-413 is a potent, selective degrader of both IRAK4 and IMiD substrates in DLBCL cells
  
  KT-413 leads to greater cell kill in MYD88<sup>MT</sup> cell lines compared to IMiDs or IRAK4 degraders or inhibitors

- KT-413 inhibits both MYD88-dependent NFκB signaling and upregulates Type1 IFN pathways, consistent with the dual-targeting activity of this molecule
  
  This combined mechanism targeting two complementary pathways leads to greater cell death than either IRAK4 or IMiD substrate degradation alone

- KT-413 shows strong <em>in vivo</em> activity on intermittent dosing schedules in MYD88-mutant DLBCL

- The combined MYD88 and IMiD pathway inhibition of KT-413 drives single-agent regression in CDX and primary PDX models
  
  Superior to the clinically active compounds CA-4148 (IRAK4 inhibitor) and CC220 (IMiD)

- KT-413 shows strong synergistic activity in combination with Rituxan or BCL2 inhibitors
  
  Induces deep and durable regressions supporting clinical investigation of these combinations

- IND filing is planned in 2H 2021 and initiation of Phase 1 clinical trial in relapsed/refractory B cell lymphomas, including MYD88-mutant DLBCL